Skip to main content

Lexeo Therapeutics, Inc.

LXEO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001907108

In the last 90 days, Lexeo Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 141 institutions reported holding it in 13F filings for Q2 2026, worth $410.9M in total; no superinvestor holds it.

13F holders, Q4 2025

Institutional positions in Lexeo Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
146
+38 vs. Q3 2025
Shares held
76.5M
+27.1M (+55.0%) vs. Q3 2025
Total value
$759.2M
+$431.7M (+131.8%) vs. Q3 2025
New holders
47
61 more added
Sold out
9
26 more reduced

1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting LXEO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2025: 146 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 0 institutionsQ1 2022: 0 institutionsQ2 2022: 0 institutionsQ3 2022: 0 institutionsQ4 2022: 0 institutionsQ1 2023: 0 institutionsQ2 2023: 0 institutionsQ3 2023: 0 institutionsQ4 2023: 31 institutionsQ1 2024: 54 institutionsQ2 2024: 60 institutionsQ3 2024: 69 institutionsQ4 2024: 90 institutionsQ1 2025: 88 institutionsQ2 2025: 90 institutionsQ3 2025: 109 institutionsQ4 2025: 146 institutionsQ1 2026: 139 institutionsQ2 2026: 141 institutions
Value heldQ4 2025: $759.2M
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $0Q1 2022: $0Q2 2022: $0Q3 2022: $0Q4 2022: $0Q1 2023: $0Q2 2023: $0Q3 2023: $0Q4 2023: $217.1MQ1 2024: $361.5MQ2 2024: $426.3MQ3 2024: $268.8MQ4 2024: $194.2MQ1 2025: $100.0MQ2 2025: $169.9MQ3 2025: $327.5MQ4 2025: $759.2MQ1 2026: $458.7MQ2 2026: $410.9M
Institutions holding LXEO and their total value by quarter
QuarterHoldersValue
Q2 2026141$410.9M
Q1 2026139$458.7M
Q4 2025146$759.2M
Q3 2025109$327.5M
Q2 202590$169.9M
Q1 202588$100.0M
Q4 202490$194.2M
Q3 202469$268.8M
Q2 202460$426.3M
Q1 202454$361.5M
Q4 202331$217.1M
Q3 20230$0
Q2 20230$0
Q1 20230$0
Q4 20220$0
Q3 20220$0
Q2 20220$0
Q1 20220$0
Q4 20210$0
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q4 2025

Shares, value and share of portfolio for each institution holding Lexeo Therapeutics, Inc.; share changes are against Q3 2025.

Institutions holding LXEO in Q4 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Bank of New York Mellon Corp166,749$1.66M0.00%+95,072+132.6%Added
Spruce Street Capital LP175,000$1.74M0.57%+175,000New
Barclays PLC188,754$1.87M0.00%+77,175+69.2%Added
Charles Schwab Investment Management Inc192,210$1.91M0.00%+86,450+81.7%Added
Privium Fund Management B.V.192,550$1.91M0.35%+194+0.1%Added
Nuveen, LLC211,529$2.10M0.00%+178,427+539.0%Added
Renaissance Technologies LLC217,772$2.16M0.00%+68,472+45.9%Added
Y-Intercept (Hong Kong) Ltd231,163$2.30M0.05%+231,163New
Ameriprise Financial Inc243,294$2.42M0.00%+76,756+46.1%Added
BNP Paribas Arbitrage, SA257,417$2.56M0.00%+226,690+737.8%Added
UBS Group AG281,083$2.79M0.00%+31,174+12.5%Added
AQR Capital Management LLC337,386$3.35M0.00%−10,537−3.0%Reduced
DAFNA Capital Management LLC340,859$3.38M0.79%−17,224−4.8%Reduced
Two Sigma Investments, LP400,567$3.98M0.01%+315,804+372.6%Added
Verition Fund Management LLC428,458$4.25M0.02%+13,595+3.3%Added
Northern Trust Corp457,052$4.54M0.00%+220,599+93.3%Added
Invesco Ltd.463,029$4.60M0.00%+463,029New
D. E. Shaw & Co., Inc.480,205$4.77M0.00%+467,387+3,646.3%Added
Ikarian Capital, LLC513,011$5.09M0.66%−54,590−9.6%Reduced
Silverarc Capital Management, LLC617,608$6.13M0.89%−161,003−20.7%Reduced
Siren, L.L.C.720,622$7.16M0.21%+117,187+19.4%Added
Goldman Sachs Group Inc781,855$7.76M0.00%+639,453+449.0%Added
Dimensional Fund Advisors LP862,892$8.57M0.00%−49,641−5.4%Reduced
Blackstone Group Inc.904,959$8.99M0.04%−219,963−19.6%Reduced
Millennium Management LLC908,024$9.02M0.01%−1,405,618−60.8%Reduced
Nantahala Capital Management, LLC1,000,000$9.93M0.59%+1,000,000New
683 Capital Management, LLC1,120,000$11.1M0.92%+197,338+21.4%Added
Suvretta Capital Management, LLC1,250,000$12.4M0.31%+1,250,000New
ADAR1 Capital Management, LLC1,393,161$13.8M1.03%−138,792−9.1%Reduced
Geode Capital Management, LLC1,445,887$14.4M0.00%+724,006+100.3%Added
Balyasny Asset Management LLC1,635,026$16.2M0.03%−2,278,762−58.2%Reduced
Octagon Capital Advisors LP1,725,000$17.1M2.14%+1,725,000New
Point72 Asset Management, L.P.1,894,722$18.8M0.03%−47,127−2.4%Reduced
OrbiMed Advisors LLC2,125,000$21.1M0.43%+2,125,000New
State Street Corp3,187,722$31.7M0.00%+2,642,877+485.1%Added
Woodline Partners LP3,197,760$31.8M0.12%+625,598+24.3%Added
Affinity Asset Advisors, LLC3,200,000$31.8M2.28%−670,527−17.3%Reduced
Avoro Capital Advisors LLC3,300,000$32.8M0.32%+3,300,000New
Citadel Advisors LLC3,774,317$37.5M0.03%+55,274+1.5%Added
Vanguard Group Inc3,894,310$38.7M0.00%+1,668,020+74.9%Added
Frazier Life Sciences Management, L.P.4,424,725$43.9M1.18%00.0%Unchanged
Vestal Point Capital, LP4,475,000$44.4M1.63%+1,225,000+37.7%Added
Paradigm Biocapital Advisors LP4,763,198$47.3M1.27%+4,763,198New
BlackRock, Inc.4,907,563$48.7M0.00%+2,736,471+126.0%Added
Ra Capital Management, L.P.5,000,000$49.6M0.51%+5,000,000New
Janus Henderson Group PLC5,509,635$54.7M0.02%−595,892−9.8%Reduced
D1 Capital Partners L.P.SuperinvestorD1 Capital Partners0$00.00%−978,652−100.0%Sold out
Palumbo Wealth Management LLC0$00.00%−61,276−100.0%Sold out
Virtu Financial LLC0$00.00%−43,269−100.0%Sold out
ExodusPoint Capital Management, LP0$00.00%−27,380−100.0%Sold out
HRT Financial LP0$00.00%−21,510−100.0%Sold out
Brevan Howard Capital Management LP0$00.00%−18,400−100.0%Sold out
Axq Capital, LP0$00.00%−14,921−100.0%Sold out
Scientech Research LLC0$00.00%−13,502−100.0%Sold out
SRS Capital Advisors, Inc.0$00.00%−4,551−100.0%Sold out
Cubist Systematic Strategies, LLC––––Not filed